Metraipolis › archive › dc_5dbba488758a

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients… — Europe PMC PMID:41286382

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41286382
DOI
10.1007/s10238-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-08T07:11:50.971Z
SHA-256 of the archived text
674a44e32555b0318fed2241abf153fddd3c7da8e0528c0e1343d81362860ca3
Stable URL of this page
https://metraipolis.com/documento/dc_5dbba488758a

How to cite

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients… — Europe PMC PMID:41286382 — Europe PMC (en), https://europepmc.org/article/MED/41286382 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5dbba488758a (Metraipolis archive dc_5dbba488758a, sha256 674a44e32555b0318fed2241abf153fddd3c7da8e0528c0e1343d81362860ca3)
BibTeX
@misc{dc5dbba488758a,
  title = {A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients… — Europe PMC PMID:41286382},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41286382},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5dbba488758a; sha256 674a44e32555b0318fed2241abf153fddd3c7da8e0528c0e1343d81362860ca3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41286382. Agents can read the archived copy with the MCP tool read_document.